Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol
1 other identifier
interventional
30
1 country
1
Brief Summary
This pilot study will try to minimize the pain during exposure to a new red light source (RhodoLED®, Biofrontera Bioscience GmbH, Leverkusen, Germany) used for PDT without compromising its effect on AKs. The study design will have an open and prospective, two-armed, split-face design. Participants with AK lesions distributed symmetrically on the scalp, forehead, cheeks, torso, back, arms and/or dorsal parts of the hands are eligible for inclusion. The purpose is to investigate if a modified irradiation protocol can lower the pain while having the same effect on AK clearance rates as compared to the standard PDT irradiation protocol. Before any study-related procedures are performed, the participants will be thoroughly informed about the study and will be given the opportunity to ask questions. The participants will thereafter sign and date the informed consent form. This constitutes as visit 0. On visit 1, a randomization to either the standard or the modified irradiation protocol will be performed on one side of the face/body and the other irradiation protocol will then be applied on the other side of the face/body. The participants should have AKs on two comparable sites, i.e. two cheeks, arms or dorsal parts of the hands. One side will be randomized to receive PDT with BF200-ALA and irradiation with the RhodoLED® lamp and the other side will receive BF200-ALA and the Aktilite CL-128 lamp (PhotoCure ASA, Oslo, Norway), which is the traditional lamp used at our department as mentioned above. The treatment will be given at visit 1. During the treatment, the participants will be asked continuously, every third minute, to estimate the pain on each treatment side using the visual analogue scale, VAS, (where 0 is no pain and 10 is the worst pain imaginable). At the end of the treatment, the participants will also be asked to summarize the treatment as a whole on the VAS-scale. After visit 1, the participants will fill in a follow-up diary form with questions regarding adverse effects (AEs) during the hours and days after the treatment. The efficacy of the treatment will also be assessed at a follow-up (FU) visit, visit 2. The investigators are aiming for a non-inferior analysis, i.e. the new modified irradiation protocol should be at least as good as the standard irradiation protocol. The randomization is blinded for the investigator at the FU visit to minimize the possibility of favoring one irradiation protocol.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2015
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2015
CompletedFirst Submitted
Initial submission to the registry
December 15, 2015
CompletedFirst Posted
Study publicly available on registry
December 31, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2017
CompletedMay 10, 2017
May 1, 2017
1.2 years
December 15, 2015
May 9, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Pain assessment
Pain is assessed on a visual analog scale from 0 to 10 (0=no pain at all, 10=worst pain imaginable). The patient assesses the pain during and after the illumination phase of PDT on both treatment sides.
Directly after PDT
Secondary Outcomes (1)
Effectiveness of PDT with the RhodoLED lamp
3 months after treatment
Study Arms (4)
Left side first -Aktilite CL128
OTHERRandomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
Right side first -Aktilite CL128
OTHERRandomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
Left side first -BF-RhodoLED
OTHERRandomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
Right side first -BF-RhodoLED
OTHERRandomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
Interventions
Infrared light, with total dose of 37J/cm2.
Infrared light, with total dose of 37J/cm2.
Prodrug applied to whole treatment area previous to illumination with either light source.
Eligibility Criteria
You may qualify if:
- Patients with symmetrically distributed AKs on the scalp, forehead, cheeks, torso, back, arms and/or dorsal parts of the hands.
- Patients \>18 years of age who have signed a written informed consent.
You may not qualify if:
- Pregnant or breast-feeding.
- Participating in other clinical study at the same time or within 30 days.
- Conditions associated with poor protocol compliance, e.g. excessive use of alcohol or drug abuse.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dep. of Dermatology, Sahlgrenska University Hospital
Gothenburg, 41345, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
John Paoli, Assoc. Prof.
Dep. of Dermatology, Sahlgrenska University Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, Assoc. Prof.
Study Record Dates
First Submitted
December 15, 2015
First Posted
December 31, 2015
Study Start
December 1, 2015
Primary Completion
March 1, 2017
Study Completion
March 1, 2017
Last Updated
May 10, 2017
Record last verified: 2017-05